[2-(3H-Imidazol-4-yl)-ethyl]-(2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine | 443118-47-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: [2-(3H-Imidazol-4-yl)-ethyl]-(2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine
• 英文别名: N-[2-(1H-imidazol-5-yl)ethyl]-2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
• CAS: 443118-47-6
• 化学式: C₁₇H₁₆N₆
• 分子量: 304.354
• InChiKey: FXLDMTQKAKJSPA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  82.3
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Compounds specific to adenosine a1 and a3 receptors and uses thereof
  申请人：Castelhano L. Arlindo

  公开号：US20050090513A1

  公开（公告）日：2005-04-28

  This invention pertains to compounds which specifically inhibit the adenosine A 1 and A 3 receptors and the use of these compounds to treat a disease associated with A3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.

  本发明涉及特定抑制腺苷A1和A3受体的化合物，以及使用这些化合物治疗与A3腺苷受体相关的疾病的方法，包括向患者施用有效治疗剂量的这些化合物。
• Compounds specific to adenosine A3 receptor and uses thereof
  申请人：——

  公开号：US20030073708A1

  公开（公告）日：2003-04-17

  This invention pertains to compounds which specifically inhibit the adenosine A 3 receptor and the use of these compounds to treat a disease associated with A 3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.

  本发明涉及特异性抑制腺苷A3受体的化合物，以及使用这些化合物治疗与A3腺苷受体相关的疾病，包括向受体中施加治疗有效量的化合物。
• 2-ARYL pyrrologpyrimidines for A1 and A3 receptors
  申请人：Castelhano Arlindo L.

  公开号：US20090192177A1

  公开（公告）日：2009-07-30

  This invention pertains to compounds which specifically inhibit the adenosine A 1 and A 3 receptors and the use of these compounds to treat a disease associated with A 3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.

  本发明涉及特异性抑制腺苷A1和A3受体的化合物，以及使用这些化合物治疗与A3腺苷受体相关的疾病的方法，包括向患者施用治疗有效量的化合物。
• Pyrrolo[2,3-d]pyrimidine derivatives which are antagonists of adenosine A1, A2A, and A3
  申请人：OSI Pharmaceuticals, Inc.

  公开号：EP1731520A1

  公开（公告）日：2006-12-13

  This invention pertains to pyrrolo [2,3-d] pyramidine derivated compounds which specifically inhibit the adenosine A1, A2A and A3 receptors and the use of these compounds to treat a disease associated with A1, A2A and A3 adenosine receptors in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.

  本发明涉及专门抑制腺苷 A1、A2A 和 A3 受体的吡咯并[2,3-d]吡脒衍生物化合物，以及使用这些化合物治疗受试者体内与腺苷 A1、A2A 和 A3 受体相关的疾病，包括给受试者施用治疗有效量的化合物。
• Compounds specific to adenosine A1 and A3 receptors and uses thereof
  申请人：OSI Pharmaceuticals, Inc.

  公开号：EP1450811B1

  公开（公告）日：2009-10-21